Sarah Houlton
Dr Sarah Houlton has a PhD in organic synthesis from Imperial College, and has been a science journalist specialising in chemistry-related topics since the early 1990s. Starting at the Journal of the Society of Dyers & Colourists, she then moved to the pharmaceutical industry magazine Manufacturing Chemist, ultimately becoming its editor. She has been freelance since 2001, and covers both science and business, with a particular interest in the pharma & biotech sector and the polyurethane industry, and the occasional foray into topics such as food ingredients and process engineering. She has been based in Boston, MA, US since 2011.
NewsLiquid cats triumph at Ig Nobels
Papers on cats, vampire bats, digeridoos and cheese disgust all won at science’s most irreverent ceremony
SponsoredIn-house training speeds up metabolism
Business plugs DMPK skills gap to improve drug discovery
BusinessAmplifying intelligent drug design
This year’s Chemistry World Entrepreneur of the year is Andrew Hopkins of start-up Exscientia and the University of Dundee, UK
BusinessFDA asks Endo to take pain drug off market
Request part of larger strategy to address opioid misuse in the US
SponsoredSygnature Discovery
Sygnature Discovery is part of an innovative partnership to bolster the life science sector in Nottingham
FeatureThe natural food dye revolution
As consumers turn their backs on artificial food colorants, food scientists learn how to work with natural alternatives. Sarah Houlton investigates
BusinessClinical trial death highlights hazards
Pain drug trial has left one dead and five hospitalised in France, with little indication as to the cause of the problems
BusinessAll part of the service
Simon Hirst, founder of contract research organisation Sygnature, is the 2016 Chemistry World entrepreneur of the year
BusinessPharmaceutical industry roundup of 2016
Controversial approvals and price clashes characterised 2016 in pharma
FeatureUS water crisis
The problems that the US city of Flint had with its water were just the first drip in a wider problem, finds Sarah Houlton
BusinessCholesterol drug withdrawn in patent dispute
Ruling that Regeneron’s Praluent antibody infringes Amgen’s Repatha patent could stifle innovation
BusinessCrispr patent ruling breaks deadlock
Both sides claim victory as board rules patents do not interfere with each other
BusinessLilly loses arbitration over Canadian patents
Firm had sought recompense under the Nafta trade agreement
BusinessOnline tool tracks bio-based materials
E-certificates automatically trace ingredients through supply chain processes
BusinessHuntsman and Clariant agree merger deal
Uniting Huntsman’s bulk materials with Clariant’s additives gives a more integrated speciality chemicals offering
FeatureAccess to drugs: a failure of pharma?
Many people around the world are either unable to afford the drugs they need, or their conditions have not been addressed by pharma R&D. Sarah Houlton investigates
CareersLearn to speak engineering
Chemists and chemical engineers are two groups separated by a common science. Sarah Houlton looks at a course that’s bridging the gap
- Business
Amgen snaps up Onyx in huge biotech deal
$10.4 billion acquisition will expand firm’s oncology portfolio
